Latest Strategic Outlook News

Hamelin Gold's latest soil sampling at the Anderson project in WA reveals strong gold anomalism, identifying new bedrock sources and expanding the project area to 500km². Further sampling aims to refine drill targets in this promising Wheatbelt region.

Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.

Yandal Resources reports significant gold mineralisation at its Siona and Caladan prospects, underpinning a robust cash position and an active 2025 exploration agenda.

N1 Holdings Limited reports robust growth in revenue, EBITDA, and profitability for the December 2024 quarter, underpinned by disciplined risk management and a refined funding strategy.

Auking Mining Limited reported a challenging quarter ending December 31, 2024, with significant cash outflows and a critical need for new capital to sustain exploration activities in Tanzania and Cloncurry.

Raiz Invest Limited reports robust growth in Q2 FY25 with active customers rising 8.5% year-on-year and funds under management surging 32.4%, underpinned by product innovation and strong net inflows.

Core Energy Minerals has raised $3.7 million through a two-tranche share placement, attracting a significant investment from Jose Luis Manzano. The funds will underpin exploration efforts across South Australia, Brazil, and Namibia, positioning the company for growth in tier-one uranium jurisdictions.

Pacgold Limited's latest drilling results and historic data recalculations at the Alice River Gold Project reveal a substantial bulk tonnage gold system, with multiple new targets identified for 2025 exploration.

Legacy Minerals is ramping up exploration across its NSW portfolio, initiating large-scale geophysical surveys and updating mineral resource estimates, setting the stage for significant drilling campaigns in 2025.

XPON Technologies reports a modest 2% increase in martech revenue and a strong cash position for Q2 FY25, while navigating an 8% decline in annualised recurring revenue amid strategic sales recalibration.

Nuix projects solid growth in Annualised Contract Value and revenue for the first half of FY25, despite elongated procurement timelines and increased contract complexity.

EMVision Medical Devices reports strong progress in clinical trials for its emu™ Bedside Scanner, backed by robust cash reserves and strategic non-dilutive funding. The company is poised to commence pivotal FDA validation trials, marking a key step toward commercialisation.